Recessive Dystrophic Epidermolysis Bullosa Clinical Trials 2026 — Find Recruiting Studies

About Recessive Dystrophic Epidermolysis Bullosa

Recessive dystrophic epidermolysis bullosa is a severe, life-limiting inherited blistering disorder caused by biallelic loss-of-function mutations in COL7A1, encoding type VII collagen — the primary structural component of anchoring fibrils at the dermal-epidermal junction. Absence or severe reduction of anchoring fibrils renders the skin and mucous membranes extraordinarily fragile, resulting in blistering and wounding from minimal mechanical trauma. Chronic wounds, pseudosyndactyly, oesophageal strictures, and a markedly elevated risk of aggressive squamous cell carcinoma constitute the major disease burden and determine prognosis.

Common Clinical Features

Generalised blistering from birth in response to minimal friction or trauma, affecting all body surfaces Chronic wounds and scarring leading to progressive pseudosyndactyly (mitten-hand deformity) of hands and feet Oesophageal blistering and strictures causing severe dysphagia, malnutrition, and failure to thrive Anaemia of chronic disease from persistent open wounds and poor nutritional absorption Corneal erosions and eye involvement causing photophobia and visual impairment Dental enamel hypoplasia and extensive dental caries from oral mucosal fragility Markedly elevated risk of aggressive, metastatic cutaneous squamous cell carcinoma, the leading cause of death in adults

Clinical Trial Eligibility Tips

What to know before applying to Recessive Dystrophic Epidermolysis Bullosa trials.

Gene therapy and cell therapy trials for RDEB typically require biallelic COL7A1 pathogenic variant confirmation; submit sequencing reports showing both variants with their predicted functional consequences.

SCC screening status is a critical safety eligibility factor — ensure current full-body dermatological examination and, where indicated, imaging or biopsy results are available at screening.

Nutritional status (serum albumin, body weight, EB-specific nutritional assessment) is a standard baseline measure and may affect eligibility for interventional trials; address nutritional deficiencies before screening where possible.